Officer & Director Jesse Shefferman Files Intent to Sell $882K in Stock
TARA sits 50% above its 52-week low of $2.77.
Summary
An Officer and Director of Protara Therapeutics has filed to sell over $882,000 worth of stock, following a stock option exercise.
Key Events · Ownership and Investor Activity · TARA
-
Officer & Director Intent to Sell
Jesse Shefferman, an Officer and Director, filed a Form 144 to sell 215,687 shares of common stock.
-
Significant Value
The proposed sale is valued at approximately $882,000, representing about 0.38% of the company's market capitalization.
-
Option Exercise Related
The shares were acquired through a stock option exercise on the same day as the proposed sale, suggesting a potential exercise-and-sell transaction.
-
Broader Selling Context
This intent to sell comes after the company recently approved a major increase in authorized common stock and launched a $100 million At-The-Market (ATM) offering, contributing to potential market overhang.
Analysis · TARA · Life Sciences
Jesse Shefferman, an Officer and Director, has filed a Form 144 indicating intent to sell 215,687 shares, valued at approximately $882,000. This represents a notable disposition by a key insider, especially following a stock option exercise on the same day. While potentially for liquidity or tax purposes, it adds to the overall selling pressure, particularly as the company recently approved a significant increase in authorized shares and launched a $100 million At-The-Market offering.
How filings like this one have moved
In the 30 days to Sep 16, 2026, 35.8% of the 1190 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.45%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TARA was trading at $4.16 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $233.8M. The 52-week trading range was $2.77 to $7.82. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.